FY2027 EPS Estimates for Immunocore Lifted by HC Wainwright

Immunocore Holdings plc (NASDAQ:IMCR) – Equities researchers at HC Wainwright upped their FY2027 EPS estimates for Immunocore in a research report issued on Friday, February 28th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $1.10 for the year, up from their previous forecast of $1.04. HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore’s FY2028 earnings at $4.46 EPS and FY2029 earnings at $7.96 EPS.

Several other analysts also recently issued reports on IMCR. Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Up 1.3 %

Shares of NASDAQ IMCR opened at $29.25 on Monday. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The company has a market cap of $1.46 billion, a P/E ratio of -30.79 and a beta of 0.77. Immunocore has a 1 year low of $27.69 and a 1 year high of $67.30. The firm has a 50-day simple moving average of $30.10 and a two-hundred day simple moving average of $31.71.

Hedge Funds Weigh In On Immunocore

Several institutional investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. purchased a new position in Immunocore during the fourth quarter valued at approximately $4,868,000. GF Fund Management CO. LTD. purchased a new position in Immunocore during the fourth quarter valued at approximately $25,000. Woodline Partners LP increased its holdings in Immunocore by 19.4% during the fourth quarter. Woodline Partners LP now owns 328,059 shares of the company’s stock valued at $9,678,000 after buying an additional 53,378 shares during the period. Tang Capital Management LLC increased its holdings in Immunocore by 40.7% during the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock valued at $45,890,000 after buying an additional 450,000 shares during the period. Finally, Tema Etfs LLC purchased a new position in Immunocore during the fourth quarter valued at approximately $330,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.